Background: The combination of tenofovir and efavirenz with either lamivudine or emtricitabine (TELE) has proved to be highly effective in clinical trials for first-line treatment of HIV-1 infection. However, limited data are available on its efficacy in routine clinical practice.
Introduction
For treatment of HIV-1, regimens consisting of tenofovir disoproxil fumarate (tenofovir) and efavirenz combined with either lamivudine or emtricitabine (TELE) are among the WHO-recommended regimens for initial HIV therapy 1 and are recommended as firstline ART in European and American guidelines. 2 Emtricitabine only differs in molecular structure from lamivudine in an added fluorine atom, and similar antiviral activity has been shown in vitro. 3 To reduce the pill count and improve adherence to The efficacy of TELE has been extensively studied in several clinical registration trials. 4 -10 An efficacy of 76% -84% has been reported (HIV-1 RNA load ,50 copies/mL) at 48 weeks using ITT analysis. Virological failure occurred in 5% -16% of patients, depending on the protocol definition. Adverse events reported in clinical trials with TELE include CNS toxicity, such as depression, abnormal dreams, attention disorders and dizziness. 11 A recent study by Scourfield et al. 12 showed that these events are also the leading effects of toxicity with Atripla w in clinical practice, frequently leading to change of therapy. Unfortunately, there is a lack of large multicentre cohort studies on the efficacy of TELE in clinical practice that allow efficacy analyses independent of co-formulation. Moreover, no studies are currently available on resistance mutations selected under TELE in clinical practice and the choice and success of second-line therapy following virological failure on TELE.
Within the European Society for translational Antiviral Research (ESAR), we sought to investigate the efficacy of TELE in clinical practice and to evaluate current European practice in second-line treatment selection and efficacy following virological failure on TELE.
Methods

Study design
The ESAR 10-01 study was designed as a retrospective cohort analysis. Anonymized data on all consecutive therapy-naive adult patients who initiated TELE in 13 clinical centres before 1 July 2009 in eight European countries were included (Table 1) . Patients were included if their age was ≥18 years and if they had received at least 4 weeks of treatment. Data generated until 1 July 2010 were collected.
The participating centres were University Hospital Ghent and University Hospital Leuven, Belgium; University Hospital for Infectious Diseases, Zagreb, Croatia; University Hospital of Cologne, Germany; Sheba Medical Center, Tel-Aviv, Israel; centres from the ARCA study group, Italy; Centre Hospitalier de Luxembourg, Luxembourg; Catharina Hospital, Erasmus Medical Center, Rijnstate Hospital, University Medical Center Groningen and University Medical Center Utrecht, all in the Netherlands; and Hospital Trias i Pujol, Spain. Patients either participated in therapy evaluation cohorts or signed a general waiver for scientific research. A check for double submissions was performed initially based on age, sex and country of birth. The primary endpoint was the proportion of patients reaching a viral load (VL) of ,50 copies/mL on TELE at 48 weeks. Efficacy was assessed according to ITT (counting missing data and patients switching to second-line therapy as failure) and on-treatment (OT) analysis. Virological failure was defined as: (i) HIV-1 RNA .200 copies/mL following previous suppression to ,50 copies/mL; (ii) a rise of 1 log 10 following previous suppression of at least 1 log 10 , both criteria in the absence of resuppression on TELE on the consecutive HIV-1-RNA assessment; or (iii) never reached VL ,200 copies/mL.
Study patients
Demographic data (age, sex, country of birth) and disease-related data [risk group, CDC class, hepatitis B surface antigen (HBsAg) status at baseline] were recorded. For first-and second-line regimen analysis, CD4 cell counts and VL results were collected. In addition, reasons for discontinuation of first-line therapy and choice of second-line regimens were collected. A switch from lamivudine to emtricitabine or vice versa and treatment simplification to a co-formulated drug were considered a formula switch and not a switch to a second-line regimen.
Resistance and subtype analysis
Baseline HIV pol population sequences were collected at baseline and time of failure, if available. The viral subtype was determined using the REGA 13, 14 Major resistance mutations in protease and reverse transcriptase (RT) were defined as listed by the International AIDS Society-USA. 15 The Stanford HIVdb algorithm version 6.2.0 16 was used to calculate non-weighted genotypic susceptibility scores (GSSs). For each drug, 'susceptible' and '(potential) low-level resistance' were scored as 1 point, 'intermediate resistance' as 0.5 points and 'high-level resistance' as 0 points. The total GSS of a regimen was calculated as the sum of the scores for the individual drugs.
Statistical analysis
SPSS software version 20.0.0 (IBM Corp., USA) and R version 3.0.1 (Foundation for Statistical Computing, Austria) were used. Proportions were compared using x 2 analysis. To identify factors associated with virological failure, multilevel, multivariate logistic regression analysis was carried out using R. For categorical variables, the category 'missing' was introduced to include all patients in the multivariate analysis, regardless of missing data. Multilevel analysis was performed to correct for bias induced by a particular centre or year of therapy initiation. The following variables were investigated: country of birth (European versus non-European), route of transmission, baseline HIV-1 RNA count, baseline CD4 count (,200 versus .200 cells/mm 3 ), baseline HBsAg status, CDC class (A/B versus C), GSS for the first-line regimen and lamivudine versus emtricitabine-based regimens. Variables were selected and goodness of fit was determined using the 22 log likelihood ratio. Since no formula switches were performed before virological failure occurred, it was possible to perform a subgroup analysis of patients using TELE as separate constituents (non-co-formulated regimens). Survival analysis (KaplanMeier) was used to compare the time to virological failure between emtricitabine-and lamivudine-based regimens. The groups were compared using a log-rank test. All CIs are 95% CIs. For all analyses, P values of ,0.05 were considered statistically significant.
Results
Population description
Data on 1608 HIV-1 patients in 13 European centres were analysed. Baseline characteristics are shown in Table 1 . Eighty-one percent of patients were male and the median age was 38.5 years. Fifty percent of patients belonged to the MSM risk group. Seventy-four percent of patients were born in Europe, whereas 13.1% were born in Africa. Co-infection with hepatitis B at baseline (positive HBsAg) was observed in 12.8% of patients. Twenty percent were diagnosed with AIDS (CDC class C) at the time of therapy initiation. Median CD4 count at baseline was 234 cells/mm 3 .
The median year of therapy initiation was 2007 (IQR 2006-08).
A baseline genotype was available for 53.6% (n ¼ 864) of patients. Sixty-six percent were infected with HIV-1 subtype B. In 18.2% (n ¼ 157) of patients at least one drug resistance mutation in the RT gene was observed ( Table 2 ). The K103R/N mutation was observed in 1.7% (15/864) at baseline and M184V was observed in 0.7% (n¼ 6) of patients. Drug sensitivity assessment using Stanford HIVdb found that 96.3% of patients had a GSS for the baseline regimen of 3 points. Patients started TELE after a median 35 (IQR 7.0 -148) weeks following diagnosis.
Endpoints
At week 48, high virological suppression rates were achieved; a VL of ,50 copies/mL was reached by 91.5% of patients according to the OT analysis and by 70.6% according to the ITT analysis (Figure 1) . At week 48, virological suppression (,50 copies/mL) was reached in 91.3% (848/929, OT) and 71.8% (848/1181, ITT) of patients on emtricitabine and in 92.3% (287/311, OT) and 67.2% (287/427, ITT) of patients on lamivudine (OT, P ¼ 0.583; ITT, P ¼ 0.074). TELE was discontinued in 370 patients (22.9%) before week 48. Reasons for discontinuation were recorded for 288 patients (78%), as shown in Table 3 . Toxicity was the major reason for discontinuation (121/288, 42.0%). This was predominantly related to CNS toxicity, which is a well-known adverse Table 2 . Baseline resistance mutations NRTI mutation n NNRTI mutation n
Baseline resistance testing was performed in 873 out of 1621 patients (53.8%). All major International Antiviral Society (IAS)-USA resistance mutations 15 are shown. Swartz et al.
reaction to efavirenz. CNS toxicity did not occur only as an acute event, but also occurred later on during treatment: per month of treatment, the proportion of patients discontinuing due to CNS toxicity was comparable (data not shown). Discontinuation because of virological failure was rare and only observed in 3.3% of cases (n¼ 53) at week 48. Virological failure was detected after a median time of 18 weeks (IQR 15.0 -49.0). No formula switches from lamivudine to emtricitabine or vice versa had been observed in these patients, i.e. all patients experienced virological failure on the initially prescribed compounds.
Virological failure occurred in 16% (5/32) of patients who had a GSS ,3 compared with 2% (17/832) of patients who received a fully active TELE regimen with a GSS of 3 (P ¼0.001). In addition, virological failure was observed in 1.6% (19/1181) of patients on emtricitabine-containing regimens and in 8.0% (34/427) of patients on lamivudine-containing regimens (P,0.001).
In a subgroup analysis, we compared time to virological failure between patients who used co-formulated TELE regimens and those who used TELE as separate constituents in the 12 of the 13 participating centres where co-formulation was recorded (1156 patients). Of these patients, 184 used emtricitabine and 310 used lamivudine as a separate constituent. In a survival analysis of this subgroup, censoring cases of treatment simplification, virological failure occurred also more often during treatment with lamivudine than with emtricitabine ( Figure 2 ) (log-rank test: P ¼ 0.007). Survival analysis of emtricitabine, tenofovir and efavirenz as separate constituents (n¼ 184) versus Truvada w /efavirenz (n ¼ 607, log-rank test: P ¼ 0.570) or versus Atripla w (n ¼ 55, logrank test: P ¼ 0.400) did not show a significant difference in the occurrence of virological failure.
In multivariate analysis, the use of lamivudine (P, 0.001), infection with subtype B virus (P ¼ 0.011), GSS ,3 (P ¼ 0.002) and baseline CD4 count ,200 cells/mm 3 (P,0.001) were all independently associated with virological failure (Table 4 ). The proportion of patients experiencing failure per year of therapy initiation was constant for both lamivudine-and emtricitabine-containing regimens. In multilevel, multivariate analysis, the year of therapy initiation and the centre where patients were followed did not influence the results. In a subgroup analysis on 864 patients in whom baseline resistance testing had been performed, use of lamivudine versus emtricitabine (OR 7.823, 95% CI 2.937-20.836, P,0.001), CD4 count ,200 cells/mm 3 (OR 5.214, 95% CI 1.804-15.070, P ¼ 0.002) and GSS 3 versus ,3 (OR 4.598, 95% CI 1.112 -19.012, P ¼ 0.035) were also independently associated with virological failure. In this subgroup the viral subtype was no longer independently associated with failure.
Second-line regimens
In cases of virological failure, resistance testing of the pol gene was performed in only half of patients (49.1%, 26/53). Of these patients, 8 (30.8%) were on emtricitabine and 18 (69.2%) on lamivudine ( Figure 3) . The most frequently observed mutations were K103N (emtricitabine, n ¼ 5; lamivudine, n ¼ 11), K65R (emtricitabine, n ¼ 3; lamivudine, n ¼ 9) and M184I/V (emtricitabine, n ¼ 6; lamivudine, n ¼ 5). Of the 12 cases in whom K65R was selected, 2 (17%) were subtype C infections.
Following virological failure, 79.2% (42/53) of patients switched to a boosted PI and two or more NRTIs. Lopinavir/ritonavir was most often prescribed (54.7%), followed by atazanavir/ Figure 2 . Kaplan-Meier analysis of virological failure in patients on TELE as separate constituents. Patients were censored if they discontinued TELE due to non-virological failure or if they switched to a co-formulated formula (treatment simplification). Virological failure was observed more often with lamivudine (grey line) than emtricitabine (black line). Log-rank test: P¼0.007. Efficacy of TELE regimens in ART-naive patients in Europe ritonavir (17.0%) and fosamprenavir/ritonavir (5.6%) (Figure 4) . The NRTI backbone from the first-line regimen was maintained in 35.8% of cases. A single NRTI was added to the original backbone in 5.7%. In the remaining 58.5% of cases one or more NRTIs were changed. The mean GSS for the second-line regimen was 2.14 (IQR 2 -2.5) and 76% of patients started second-line therapy with a GSS ,3. Despite the presence of fewer than three active drugs, VL was suppressed to ,50 copies/mL in 73.5% and to ,200 in 85% (OT) of patients after 1 year of second-line therapy following initial virological failure on TELE. At the time of switch to second-line therapy for reasons of toxicity, 49.1% of patients were suppressed to ,50 copies/mL. Patients often (53.7%) switched to another NNRTI-based regimen; in 45.4% of switches to nevirapine the backbone was maintained. After 1 year of second-line treatment, HIV-RNA was suppressed to ,50 copies/mL in 77.8% of patients switching for reasons of toxicity (OT).
Treatment simplification
For 848/1194 (71%) of patients on emtricitabine-containing regimens, it was recorded whether they used emtricitabine, tenofovir and efavirenz, Truvada w and efavirenz or Atripla w as a singletablet regimen at baseline and at any time during follow-up, giving insight into treatment simplification. In this subgroup analysis only patients starting therapy in or after . At week 48, the proportion of patients on Atripla w had increased to 58.8% ( Figure 5 ). Patients on the separate constituents rarely switched to a co-formulated drug (12.6% at baseline and 11.6% at week 48).
Discussion
In this large multicentre, retrospective cohort analysis we found that the efficacy of TELE-based first-line regimens was lower than the efficacy reported in clinical registration trials. 6 -9 A limitation of our study design is that the reason for discontinuation in the absence of virological failure was not always recorded in clinical practice. To counter this, we introduced 'missing' as a separate category in categorical variables to include all patients in the multivariate analyses. Lower efficacy was mainly due to the occurrence of CNS-related toxicity. Similar toxicity patterns were reported in a smaller, single-country retrospective study of Atripla w as first-line therapy by Scourfield et al.
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In our cohort, virological failure was rarely observed. When failure did occur this was more common in patients infected with viral subtype B, in patients with a baseline CD4 count ,200 cells/mm 3 , in patients who received fewer than three active drugs due to baseline resistance and in patients on lamivudine compared with those on emtricitabine. A higher risk of therapy failure in patients infected with subtype B compared with non-B has also been observed in Caucasian patients on heterogeneous treatment regimens in the Swiss HIV cohort. 17 Here we report the same phenomenon in patients treated with current commonly prescribed first-line regimens, independent from VL, CD4 cell count and baseline drug resistance. Our observation of a low CD4 count as a predictor of failure has not been reported in clinical registration trials with TELE, but a low CD4 count was independently associated with the development of the K65R resistance mutation in Study 903. 18 There are only scarce data on the risk of failure in the presence of baseline resistance for specific regimens. A large retrospective international cohort study indicated an increased risk of virological failure in the absence of a fully active first-line regimen. 19 Our data show that the GSS for TELE was also an independent predictor of virological failure. These findings confirm the importance of baseline resistance testing as a valuable tool to detect patients at risk of virological failure.
The strongest predictor of virological failure in our cohort was the use of lamivudine, compared with emtricitabine. In a recent meta-analysis of the efficacy of lamivudine versus emtricitabine in heterogeneous trial populations, no significant difference in efficacy was observed between the two compounds. 20 The only trial in this meta-analysis that directly compared emtricitabine and lamivudine in TELE regimens in therapy-naive patients showed a trend towards higher efficacy with emtricitabine. 21 One difference between lamivudine-and emtricitabine-containing regimens is that co-formulated regimens of emtricitabine are available that are associated with comparable or higher adherence. 22 -24 In this study, we found comparable efficacy between co-formulated and non-co-formulated regimens containing emtricitabine. Moreover, in a subgroup analysis of patients taking TELE as separate constituents, virological failure was more often observed in patients using lamivudine, implying that differences between lamivudine-and emtricitabine-based regimens could not be attributed to co-formulation. These results suggest that, in combination with tenofovir and efavirenz, emtricitabine may be preferred to lamivudine. This observation is of crucial importance as recent WHO guidelines emphasize the equivalence of lamivudine and emtricitabine, and only lamivudine is generically available. 25 A higher rate of emergence of drug resistance mutations at failure of lamivudine compared with emtricitabine was also observed in cohorts of primarily pretreated individuals 26, 27 and in two retrospective studies that compared outcomes of lamivudine with those of emtricitabine when they were used in combination with various background regimens. 28, 29 A longer intracellular half-life for emtricitabine and more efficient incorporation of emtricitabine during HIV-1 nucleic acid synthesis have been suggested to explain this phenomenon. 26 Because of a longer halflife, patients may retain sufficiently high drug levels, even in the case of suboptimal adherence.
Upon virological failure in our cohort, resistance testing was only performed in half of the patients, indicating that blind switches to PI-based regimens often occur in clinical practice. In patients who received resistance testing, the K65R mutation in RT, conferring decreased susceptibility to all NRTIs except zidovudine, was observed in half of the patients, while the lamivudine/emtricitabine signature mutations M184V and M184I were observed less frequently. In clinical trials, selection of K65R is rare as opposed to the frequently encountered M184I and M184V variants. 4 -10 Of note, in our cohort K65R was more often selected in patients using lamivudine-containing compared with emtricitabinecontaining regimens, while the 184I and 184V mutations were equally present among both regimens. The K65R mutation has been shown to be selected more rapidly in subtype C virus in vitro 30 and in vivo. 31, 32 In our cohort, subtype distribution could not explain the frequent selection of this mutation. We hypothesize that a longer duration of virological failure and selective resistance testing in clinical practice may explain the higher occurrence of K65R observed in our cohort compared with clinical trials.
After virological failure on TELE, most patients were switched to a regimen of a ritonavir-boosted PI and two or more NRTIs, despite the fact that most patients had one or more NRTI resistance Efficacy of TELE regimens in ART-naive patients in Europe mutations. Still, second-line therapy was generally successful. This is contrary to our findings in first-line TELE, where GSS ,3 was significantly associated with a higher rate of virological failure. Similar observations of high efficacy of second-line therapy despite the presence of resistance mutations were found for ritonavir-boosted lopinavir in the SECOND-LINE study. 33 These results confirm the higher genetic barrier to resistance of boosted PIs in vivo.
Conclusions
To our knowledge, this is the largest clinical case cohort available in current literature on patients using efavirenz and tenofovir combined with either lamivudine or emtricitabine. We conclude that, in Europe, first-line treatment failure occurred relatively frequently due to toxicity, while virological failure was rare and was observed more often with lamivudine than emtricitabine. These differences could not be attributed to co-formulation. Furthermore, we observed that a GSS ,3 due to baseline resistance was a predictor of failure during first-line therapy, but not for second-line boosted PI regimens.
